Fuji Pharma (4554) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Operating and ordinary income increased significantly due to revenue growth and an improvement in the SG&A expense ratio; however, Net Income remained roughly at the previous year's level because extraordinary losses, including impairment losses on investment securities, were recorded. Revenue was ¥453.8B (¥369.5B in the previous year, +22.8%), Operating Income was ¥53.9B (+60.2%), and Ordinary Income was ¥54.8B (+73.5%), while Net Income was ¥18.2B (-0.5%), essentially flat. The primary factor behind the earnings growth was the emergence of operating leverage resulting from the lower SG&A expense ratio, while the sluggish growth in Net Income was attributable to the temporary factor of ¥33.7B in extraordinary losses, including ¥33.1B in impairment losses on investment securities.

Factors Affecting Business Performance

【Revenue】The Company operates in a single Pharmaceutical Business segment, and Revenue increased significantly to ¥453.8B (¥369.5B in the previous year, +22.8%). Although a breakdown by segment has not been disclosed, the increase appears to have been driven by higher volume and an improved product mix.

【Profit and Loss】The gross profit margin was 38.9%, down 1.0pt from 39.9% in the previous year; however, the SG&A expense ratio improved by 3.8pt to 27.0% (30.8% in the previous year), and the Operating Income margin increased by 2.8pt to 11.9% (9.1% in the previous year). In non-operating income and expenses, foreign exchange gains of ¥1.3B and other items contributed, resulting in Ordinary Income of ¥54.8B (+73.5%) and an Ordinary Income margin of 12.1%, up 3.5pt from 8.5% in the previous year. Nevertheless, as a result of recording ¥33.7B in extraordinary losses, primarily the ¥33.1B impairment loss on investment securities, Profit Before Tax declined to ¥21.1B (¥27.0B in the previous year, -21.8%), while Net Income remained nearly at the previous year's level at ¥18.2B (-0.5%). This was a case of higher revenue and higher earnings through the Ordinary Income stage, accompanied by significant growth in Operating Income and Ordinary Income but sluggish Net Income due to extraordinary losses.

Key Financial Indicators

【Profitability】The Operating Income margin improved by 2.8pt to 11.9% from 9.1% in the previous year, and the Ordinary Income margin expanded by 3.5pt to 12.1% (8.5% in the previous year), while the Net Income margin declined by 0.9pt to 4.0% from 4.9% in the previous year. 【Cash Flow Quality】Comprehensive Income was ¥28.8B, exceeding Net Income of ¥18.2B by ¥10.6B, with foreign currency translation adjustments of +¥5.9B and valuation difference on available-for-sale securities of +¥5.0B making positive contributions. 【Investment Efficiency】ROE was 3.5%, and EPS was ¥72.11 (¥75.07 in the previous year, -3.9%); the improvement at the operating level has not been fully reflected in ROE because of the extraordinary losses. 【Financial Soundness】The Equity Ratio was 52.7%, up 2.5pt from 50.2% in the previous year, while the Current Ratio was approximately 166%, indicating a sound liquidity position. Cash and deposits increased to ¥99.5B (¥72.5B in the previous year, +37.3%).

Cash Flow Analysis

As cash flow statement data is unavailable, funding trends are analyzed based on changes in the balance sheet. Cash and deposits were ¥99.5B, an increase of +¥27.0B (+37.3%) from ¥72.5B in the previous year. While Revenue increased by +22.8%, the combined balance of accounts receivable and notes receivable increased by only +9.3%, and inventories increased by +10.0%; working capital growth therefore remained below revenue growth. Accounts payable increased by +26.0%, consistent with the expansion of procurement and production activities accompanying revenue growth. Property, plant and equipment and intangible assets were broadly flat, indicating that capital investment remained restrained. Overall, the relatively moderate growth in working capital compared with revenue expansion can be viewed as a positive sign from a funding efficiency perspective.

Earnings Quality

Ordinary Income of ¥54.8B consists of Operating Income of ¥53.9B plus non-operating income and expenses, including foreign exchange gains of ¥1.3B, and is at a level reflecting the Company's core earnings power. Meanwhile, the ¥33.7B in extraordinary losses was primarily the ¥33.1B impairment loss on investment securities, which reduced Profit Before Tax and Net Income as a temporary factor associated with market fluctuations. Excluding this one-time loss, the improvement in earnings through the Ordinary Income stage appears to represent a highly sustainable structural change. Comprehensive Income was ¥28.8B, exceeding Net Income of ¥18.2B by ¥10.6B; the positive contribution from other comprehensive income items, such as foreign currency translation adjustments and valuation difference on securities, indicates an improvement in asset value that cannot be fully captured by Net Income alone.

Earnings Forecasts and Guidance

At the nine-month point, progress rates were 76.6% for Revenue, 88.1% for Operating Income, 93.2% for Ordinary Income, and 81.3% for Net Income. Operating Income and Ordinary Income are progressing at a pace significantly above the 75% benchmark, suggesting potential upside relative to the full-year plan. Although the progress rate for Net Income is somewhat lower, this reflects the temporary impact of the extraordinary losses, and neither the earnings forecast nor the dividend forecast was revised during the quarter.

Shareholder Returns

The interim dividend was ¥23 per share, representing a +15.0% increase from ¥20 in the same period of the previous year. The Payout Ratio against cumulative interim Net Income was 31.9% (¥23 dividend ÷ cumulative EPS of ¥72.11), a reasonable level. The full-year dividend forecast is ¥49, and forecast full-year EPS is ¥91.54. No share repurchases have been confirmed, and shareholder returns currently center on dividends.

Risk Factors

1. Risk of recurring impairment losses on investment securities: As a result of recording an impairment loss of ¥33.1B during the period, the balance of investment securities was halved to ¥25.1B (¥50.9B in the previous year). Additional impairment losses could arise due to market fluctuations in the Company's investment portfolio.

2. Reliance on short-term financing: Short-term borrowings amounted to ¥153.0B, while the ratio to cash and deposits of ¥99.5B was approximately 0.65x. Although the Current Ratio is 166%, a sound level, trends in the refinancing of short-term liabilities will remain an area requiring monitoring.

3. Earnings volatility from extraordinary losses: Profit Before Tax was ¥21.1B, down -21.8% from ¥27.0B in the previous year, indicating a structure in which quarterly Net Income is susceptible to fluctuations depending on whether extraordinary losses arise.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (pharma)

Profitability and Returns

Both the Company's Operating Income margin and Net Income margin are positive and significantly exceed the industry median, which includes many loss-making companies.

Growth and Capital Efficiency

The Company's Revenue growth rate demonstrates an outstanding increase, while the industry median remains in negative territory.

※Source: Compiled by the Company

Key Takeaways from the Financial Results

1. The Operating Income margin improved by 2.8pt to 11.9% (9.1% in the previous year), led by a decline in the SG&A expense ratio (-3.8pt). Progress toward full-year Operating Income is 88.1%, indicating steady progress and a fundamental improvement in earnings power.

2. Net Income remained roughly at the previous year's level (-0.5%) due to extraordinary losses, including the ¥33.1B impairment loss on investment securities. Whether the growth in Operating Income and Ordinary Income will flow through to Net Income will depend on whether additional temporary losses arise.

3. Comprehensive Income exceeded Net Income by ¥10.6B, with foreign currency translation adjustments and valuation difference on securities making positive contributions. An improvement in asset value that is difficult to discern from Net Income alone has been confirmed.

Theoretical Share Price (Reference Value)

This is a mechanically calculated reference range based solely on publicly disclosed data using a residual income model (Ohlson-type model with an explicit five-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥1,685–¥1,780 at ±1% for the cost of equity, and ¥1,723–¥1,737 at ±0.1 for ω.

Notes:

• Net Income is substantially compressed relative to Operating Income due to tax burden, acquisition-related expenses, non-controlling interests, and other factors (Net Income ÷ Operating Income 37%). This value reflects that compression at face value; if the factors are temporary, underlying earnings power may be higher.
• Because forecast ROE is below the cost of equity, the theoretical value is below Book Value per Share.
• Net assets as of the end of the quarter are used (there is a timing gap relative to the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated at a somewhat high level.

(Calculation model: Residual Income Model / Interest Rate Reference Month: 2026-07 / This value is not a forecast or guarantee of the future share price)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 performance was operationally strong, but reported net income was held back by a large non-recurring investment-security valuation loss. Cumulative revenue rose 22.8% year on year to ¥45.38bn. Operating income increased 60.2% to ¥5.39bn, materially outpacing sales growth. Ordinary income grew 73.5% to ¥5.48bn, aided by ¥0.45bn of non-operating income, including ¥0.13bn of foreign-exchange gains and ¥0.27bn of subsidy income. Gross profit increased to ¥17.67bn. The gross margin improved to 38.9%, versus 39.9% in the prior-year period, a 100bp compression despite the substantial increase in gross profit. The operating margin nevertheless expanded to 11.9% from 9.1%, an improvement of 280bp, as SG&A rose 11.8%, well below revenue growth. This positive operating leverage is the principal earnings achievement in the quarter. Net income was ¥1.82bn, down 0.6% year on year, despite the sharp operating-profit improvement. The divergence arose because extraordinary losses increased to ¥3.37bn from ¥0.46bn a year earlier. Within this amount, a ¥3.31bn loss on valuation of investment securities was the dominant item and reduced pre-tax profit to ¥2.11bn. Consequently, the cumulative net margin was 4.0%, below the operating margin and not representative of the underlying operating trajectory. Comprehensive income increased to ¥2.88bn, supported by positive securities valuation and foreign-currency translation effects. The company has maintained its full-year guidance, calling for revenue of ¥59.25bn, operating income of ¥6.12bn, ordinary income of ¥5.88bn and net income of ¥2.24bn. Q3 cumulative progress is 76.6% for revenue, 88.1% for operating income, 93.2% for ordinary income and 81.3% for net income, compared with a standard 75% Q3 pace. The above-standard operating and ordinary-income progress implies that the guidance is operationally achievable, although the remaining earnings outlook depends on the absence of additional extraordinary valuation losses and on disciplined working-capital management.

Profitability Analysis

The annualized DuPont ROE is 4.7%, decomposed into a 4.0% net profit margin, 0.615x asset turnover and 1.90x financial leverage. The constrained component is net margin, rather than asset turnover or leverage, because the extraordinary investment-security valuation loss sharply reduced net income. The 11.9% EBIT margin and 38.9% gross margin indicate a profitable underlying pharmaceutical operation, with operating margin in the sector's generally good 8-15% range. Operating margin expanded by 280bp year on year, from 9.1% to 11.9%, as revenue growth of 22.8% exceeded SG&A growth of 11.8% by roughly 1,100bp. This is favorable operating leverage and suggests that incremental sales are being converted efficiently into operating income. Gross margin declined by about 100bp year on year, indicating that the operating-margin gain was driven primarily by SG&A absorption rather than improved product gross profitability. The extended DuPont tax burden was healthy at 0.862, equivalent to a 13.7% effective tax rate. The reported interest burden of 0.391 is weak mechanically, but its root cause is the ¥3.37bn extraordinary loss between EBIT and pre-tax income, rather than recurring financing cost: interest expense was ¥0.29bn and interest coverage was a solid 18.79x. Therefore, the quality alert stating that 61% of EBIT was consumed by interest should not be interpreted as actual cash interest absorption. Financial leverage of 1.90x and D/E of 0.90x indicate moderate balance-sheet leverage rather than an aggressive capital structure. The principal sustainability question is whether revenue growth and SG&A discipline can continue while protecting gross margin; the investment-security loss should be treated separately from recurring operating profitability.

Growth Assessment

Revenue growth of 22.8% to ¥45.38bn provides a strong base for the full-year sales forecast of ¥59.25bn. The 76.6% Q3 sales progress is only modestly above the standard 75% pace, indicating that Q4 still requires normal execution rather than an unusually weak finish. Operating income growth of 60.2% substantially exceeded sales growth, reflecting operating leverage. Operating-income progress of 88.1% is 13.1 percentage points above the standard Q3 pace and exceeds the stated 10% deviation threshold. Ordinary-income progress of 93.2% is also well ahead of the standard pace, supported in part by foreign-exchange gains and subsidy income. Net-income progress of 81.3% remains ahead of the standard pace but is less pronounced because the investment-security valuation loss offset operating gains. Full-year guidance implies Q4 revenue of ¥13.87bn, operating income of ¥0.73bn, ordinary income of ¥0.40bn and net income of ¥0.42bn. The implied Q4 operating margin is approximately 5.3%, substantially below the cumulative 11.9% margin, pointing to expected seasonality, costs, or conservatism in the unchanged forecast. As a single-segment pharmaceutical business, the group does not provide segment-level revenue or operating-income diversification. The growth outlook should be assessed through sales momentum, gross-margin protection, operating-cost discipline, and the recurrence of valuation-related extraordinary charges.

Financial Health

Liquidity is sound on reported balance-sheet measures, with a current ratio of 165.9%, a quick ratio of 144.0%, and working capital of ¥21.72bn. Current assets of ¥54.69bn exceed current liabilities of ¥32.97bn by a meaningful margin. Cash and deposits increased 37.4% year on year to ¥9.95bn, strengthening immediate liquidity. However, short-term loans were ¥15.30bn and represented 70.7% of interest-bearing debt, creating a material refinancing and maturity-concentration risk. Cash covers only 0.65x of short-term debt, so the company relies on receivables, inventory monetization and access to bank refinancing rather than cash alone for debt repayment. This risk is mitigated by the current ratio above 1.0, the quick ratio above 1.0, and solid interest coverage of 18.79x. Total interest-bearing debt was ¥21.63bn, comprising ¥15.30bn of short-term loans, ¥6.33bn of long-term loans and bonds, including current maturities. D/E of 0.90x and debt/capital of 29.4% remain within conservative-to-moderate credit benchmarks and do not indicate excessive overall indebtedness. Accounts payable rose 26.0% to ¥5.76bn, broadly supporting working capital but requiring monitoring against inventory and procurement trends. Investment securities declined 50.8% to ¥2.51bn, consistent with the significant valuation loss recorded in extraordinary items and reducing the value of this non-core asset base. Intangible assets were ¥13.55bn, or 13.8% of total assets, below the 20% concentration benchmark. Lease obligations totaled ¥4.27bn, comprising ¥0.60bn current and ¥3.67bn non-current, and should be considered alongside borrowings in assessing fixed financing commitments. Deferred tax assets were ¥3.56bn, representing a meaningful balance-sheet asset whose recoverability depends on sustained taxable profitability.

Notable B/S Changes

Investment securities: -¥2.59bn (-50.8%) to ¥2.51bn - consistent with the ¥3.31bn valuation loss on investment securities; highlights non-core asset valuation risk. Cash and deposits: +¥2.71bn (+37.4%) to ¥9.95bn - improves liquidity, but remains below ¥15.30bn of short-term loans. Accounts payable: +¥1.19bn (+26.0%) to ¥5.76bn - provides additional supplier financing, while also requiring monitoring against elevated inventory and the long cash-conversion cycle. Accounts receivable: +¥1.62bn (+11.0%) to ¥16.36bn - a large 16.6% of total assets and consistent with the 99-day DSO alert. Work in process: +¥1.09bn (+33.6%) to ¥4.32bn - supports production activity but adds to inventory funding, execution and obsolescence exposure. Total equity: +¥4.97bn (+10.6%) to ¥51.88bn - strengthens the capital base and keeps D/E at 0.90x despite the short-term debt concentration.

Cash Flow Quality

Cash-flow quality cannot be evaluated through operating cash flow, free cash flow, OCF/net-income conversion, or cash conversion from earnings because cash-flow figures are not reported in the supplied financial data. Working-capital indicators nevertheless identify a material cash-conversion concern. The quality alert for receivable days of 99 days has a clear root cause in trade receivables of ¥16.36bn, equal to 16.6% of total assets, alongside notes receivable of ¥3.31bn. For pharmaceuticals, extended collection periods can occur in institutional and wholesaler distribution channels, but 99 days is above the 60-day alert threshold and raises the possibility that revenue growth is not being converted promptly into cash. The quality alert for inventory days of 231 days indicates a substantial inventory-holding burden, consistent with raw materials of ¥11.82bn, work in process of ¥4.32bn and finished goods of ¥7.22bn. Pharmaceutical manufacturing can require safety stock, batch production and inventory buffers, but 231 days is well above the 90-day threshold and heightens expiry, obsolescence and demand-forecasting risks. A second inventory-days alert of 71 days is also above its stated 60-day threshold; irrespective of the underlying inventory definition, it confirms that inventory efficiency warrants attention. The long cash-conversion-cycle alert of 273 days is the combined consequence of slow collections and high inventory holdings, only partly offset by supplier credit. This length materially increases funding needs and compounds the short-term refinancing exposure. The increase in accounts payable to ¥5.76bn provides some working-capital financing, but it does not eliminate the need to monetize receivables and inventories. The key operating cash-flow test in subsequent reporting will be whether collections and inventory drawdown convert the strong operating-income growth into cash generation.

Dividend Sustainability

The declared Q2 dividend is ¥23 per share, and full-year guidance indicates DPS of ¥49. Based on forecast EPS of ¥91.54, the prospective dividend payout ratio is approximately 53.5%, below the 60% sustainability benchmark. The calculated cumulative payout ratio using the ¥23 interim dividend and ¥1.82bn Q3 net income is 33.5%. The full-year dividend commitment is therefore broadly consistent with forecast profitability. Retained earnings of ¥36.81bn provide a substantial accounting buffer relative to the expected dividend. However, dividend sustainability should be evaluated alongside the long working-capital cycle and the ¥15.30bn short-term loan balance. The investment-security valuation loss is non-recurring in presentation but demonstrates that reported net income can be volatile. The company has made no revision to its dividend plan. There is no basis in the supplied data to assess dividend coverage by free cash flow or total return including buybacks. Accordingly, the prospective payout appears earnings-supported, while cash realization and refinancing management remain the central variables for distribution capacity.

Risk Assessment

Business risks include Pharmaceutical demand, pricing and reimbursement risk: revenue is growing strongly, but pharmaceutical businesses remain exposed to drug-price revisions, generic competition, regulatory changes and shifts in customer procurement., Inventory risk: the 231-day inventory alert, together with ¥11.82bn of raw materials, ¥4.32bn of work in process and ¥7.22bn of finished goods, raises expiry, obsolescence, batch-planning and demand-forecasting risk., Receivables collection risk: the 99-day DSO alert indicates a slower cash-conversion profile than the stated 60-day benchmark., Margin risk: gross margin compressed by approximately 100bp year on year, so the operating-margin expansion currently relies on SG&A leverage rather than gross-margin improvement..

Financial risks include Refinancing risk: 70.7% of interest-bearing debt is short term, with ¥15.30bn of short-term loans and cash covering only 0.65x of that balance. This is the root cause of the refinancing-risk alert; the impact is greater sensitivity to lender terms and short-term funding availability., Working-capital funding risk: the 273-day cash-conversion-cycle alert links high receivable and inventory days to greater ongoing financing needs., Investment-security valuation risk: a ¥3.31bn valuation loss on investment securities drove extraordinary losses of ¥3.37bn and materially reduced pre-tax profit., Foreign-exchange sensitivity: ¥0.13bn of FX gains contributed to non-operating income during the period, indicating that ordinary income has some currency exposure., Lease and pension obligations: lease obligations of ¥4.27bn and a net defined-benefit liability of ¥2.29bn represent fixed or long-duration financial commitments in addition to debt..

Key concerns include The high-interest-burden alert requires contextual interpretation: the 0.391 EBT/EBIT ratio primarily reflects extraordinary valuation losses, not recurring interest expense, as confirmed by 18.79x interest coverage. The investment implication is earnings volatility rather than immediate debt-service stress., Operating income is tracking 13.1 percentage points ahead of a standard Q3 progress rate, while full-year guidance implies a much lower Q4 operating margin. The eventual reason for this implied deceleration is important for assessing earnings durability., Net income declined 0.6% despite 60.2% operating-income growth, demonstrating that below-the-line items can dominate reported earnings..

Investment Implications

Key takeaways include Revenue and operating income showed strong momentum, with 22.8% and 60.2% year-on-year growth, respectively., Operating margin expanded 280bp to 11.9% through favorable SG&A leverage, although gross margin declined about 100bp., The ¥3.31bn investment-security valuation loss was the principal reason net income did not reflect the operating improvement., Liquidity ratios are healthy, but the debt maturity profile and long cash-conversion cycle create a meaningful funding-management focus., Full-year guidance remains unchanged and Q3 progress is ahead of the standard pace for all major earnings lines..

Metrics to watch include Q4 operating margin versus the approximately 5.3% margin implied by full-year guidance, Receivable days and collection of the ¥16.36bn trade-receivables balance, Inventory days, raw-material and work-in-process levels, and any inventory write-downs, Short-term loan refinancing, cash-to-short-term-debt coverage, and interest expense, Further gains or losses on investment securities and the effect on pre-tax profit, Gross-margin trajectory and SG&A growth relative to revenue growth, Operating cash flow and free cash flow conversion once reported.

Regarding relative positioning, Underlying profitability is in a favorable range for a pharmaceutical manufacturer, with an 11.9% operating margin and strong interest coverage. However, the annualized 4.7% ROE is below the 8% concern threshold because exceptional investment-security losses depressed net income, while working-capital intensity and short-term debt concentration weaken the cash-efficiency profile relative to a conservatively financed peer.